Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Treatment and outcome of young patients with esophageal cancer in the Netherlands.

van Nistelrooij AM, van Steenbergen LN, Spaander MC, Tilanus HW, van Lanschot JJ, Lemmens VE, Wijnhoven BP.

J Surg Oncol. 2014 May;109(6):561-6. doi: 10.1002/jso.23533. Epub 2013 Dec 11.

PMID:
24338660
2.

Increased resection rates and survival among patients aged 75 years and older with esophageal cancer: a Dutch nationwide population-based study.

Faiz Z, Lemmens VE, Siersema PD, Nieuwenhuijzen GA, Wouters MW, Rozema T, Coebergh JW, Wijnhoven BP.

World J Surg. 2012 Dec;36(12):2872-8. doi: 10.1007/s00268-012-1762-2.

PMID:
22965535
3.

Incurable esophageal cancer: patterns of tumor spread and therapeutic consequences.

Gockel I, Kneist W, Junginger T.

World J Surg. 2006 Feb;30(2):183-90.

PMID:
16425075
4.

Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy.

Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL.

Ann Surg Oncol. 2012 May;19(5):1678-84. doi: 10.1245/s10434-011-2078-4. Epub 2011 Nov 2.

PMID:
22045465
5.

A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer.

Vallböhmer D, Hölscher AH, DeMeester S, DeMeester T, Salo J, Peters J, Lerut T, Swisher SG, Schröder W, Bollschweiler E, Hofstetter W.

Ann Surg. 2010 Nov;252(5):744-9. doi: 10.1097/SLA.0b013e3181fb8dde.

PMID:
21037429
6.

Treatment of esophageal cancer based on histology: a surveillance epidemiology and end results analysis.

Chang DT, Chapman C, Shen J, Su Z, Koong AC.

Am J Clin Oncol. 2009 Aug;32(4):405-10. doi: 10.1097/COC.0b013e3181917158.

PMID:
19415029
7.

Prognostic factors for medium- and long-term survival of esophageal cancer patients in the Netherlands.

Bus P, Lemmens VE, van Oijen MG, Creemers GJ, Nieuwenhuijzen GA, van Baal JW, Siersema PD.

J Surg Oncol. 2014 Apr;109(5):465-71.

PMID:
24783268
8.

Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.

Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K.

Ann Surg Oncol. 2013 Sep;20(9):3038-43. doi: 10.1245/s10434-013-2988-4. Epub 2013 Apr 28.

PMID:
23625142
9.

Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, Zanchettin G, Rugge M, Ancona E.

Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.

PMID:
21556952
10.

Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.

Smit JK, Güler S, Beukema JC, Mul VE, Burgerhof JG, Hospers GA, Plukker JT.

Ann Surg Oncol. 2013 Nov;20(12):4008-15. doi: 10.1245/s10434-013-3102-7. Epub 2013 Jul 10.

PMID:
23838922
11.

Total number of resected lymph nodes predicts survival in esophageal cancer.

Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, Mazumdar M.

Ann Surg. 2008 Aug;248(2):221-6. doi: 10.1097/SLA.0b013e31817bbe59.

PMID:
18650631
12.

The effect of socioeconomic status on staging and treatment decisions in esophageal cancer.

Bus P, Aarts MJ, Lemmens VE, van Oijen MG, Creemers GJ, Nieuwenhuijzen GA, van Baal JW, Siersema PD.

J Clin Gastroenterol. 2012 Nov-Dec;46(10):833-9. doi: 10.1097/MCG.0b013e31824e8ff8.

PMID:
22460163
13.

Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.

McKenzie S, Mailey B, Artinyan A, Metchikian M, Shibata S, Kernstine K, Kim J.

Ann Surg Oncol. 2011 Feb;18(2):551-8. doi: 10.1245/s10434-010-1314-7. Epub 2010 Sep 14.

PMID:
20839062
14.

Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study.

Schwer AL, Ballonoff A, McCammon R, Rusthoven K, D'Agostino RB Jr, Schefter TE.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):449-55. doi: 10.1016/j.ijrobp.2008.04.022. Epub 2008 Jun 4.

PMID:
18538500
15.

The impact of young age on outcomes in esophageal and junctional cancer.

Donohoe CL, MacGillycuddy E, Reynolds JV.

Dis Esophagus. 2011 Nov;24(8):560-8. doi: 10.1111/j.1442-2050.2011.01183.x. Epub 2011 Mar 8.

PMID:
21385286
16.

Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.

Reynolds JV, Donohoe CL, McGillycuddy E, Ravi N, O'Toole D, O'Byrne K, Hollywood D.

J Thorac Cardiovasc Surg. 2012 May;143(5):1130-1137.e1. doi: 10.1016/j.jtcvs.2011.12.003. Epub 2012 Jan 11.

17.

Targeting therapy for esophageal cancer in patients aged 70 and over.

Furlong H, Bass G, Breathnach O, O'Neill B, Leen E, Walsh TN.

J Geriatr Oncol. 2013 Apr;4(2):107-13. doi: 10.1016/j.jgo.2012.12.006. Epub 2013 Jan 29.

PMID:
24071535
18.

Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer.

Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ.

Ann Surg. 2007 May;245(5):707-16.

19.

Individualized, multimodal palliative treatment of inoperable esophageal cancer: clinical impact of photodynamic therapy resulting in prolonged survival.

Lindenmann J, Matzi V, Neuboeck N, Anegg U, Baumgartner E, Maier A, Smolle J, Smolle-Juettner FM.

Lasers Surg Med. 2012 Mar;44(3):189-98. doi: 10.1002/lsm.22006. Epub 2012 Feb 14.

PMID:
22334351
20.

Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.

Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R.

Ann Surg Oncol. 2010 Apr;17(4):1159-67. doi: 10.1245/s10434-009-0862-1. Epub 2010 Feb 6.

PMID:
20140529

Supplemental Content

Support Center